At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 302 enrolled

Drug / intervention

N-Acetylcysteine +1 moredrug

Likely dose

N-Acetylcysteine 1200mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01675661

NCT01675661Phase 3Completed

Compare CT.gov

Achieving Cannabis Cessation: Evaluating N-Acetylcysteine Treatment (ACCENT)

Medical University of South Carolina·interventional·Posted Aug 30, 2012·Updated May 24, 2018

In Brief

A Phase 3 clinical trial evaluating N-Acetylcysteine and Placebo for Cannabis Dependence. Completed, enrolled 302 participants across 6 sites.

Detailed Summary

The primary objective of this study is to evaluate the impact of N-acetylcysteine (NAC) 1200 mg versus matched placebo (PBO) twice daily, added to contingency management (CM), on cannabis use among treatment-seeking cannabis-dependent adults (ages 18-50).

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsCannabis Dependence

CountriesUnited States

CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 3CompletedFinished

20132014201520162017201820192020202120222023202420252026

First PostedAug 2012

Enrollment StartJan 2014

Primary CompletionJul 2015

Study CompletionAug 2015

TodayJul 2026

First PostedAug 30, 2012

Enrollment StartJan 1, 2014

Primary CompletionJul 1, 2015

Study CompletionAug 1, 2015

TodayJul 2, 2026

Enrollment to primary: 1.5 yearsPosted 13.8 years ago

Interventions

N-Acetylcysteinedrug

Study participants randomly assigned to the NAC arm will receive a 12-week course of N-Acetylcysteine (1200mg) twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.

Placebodrug

Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.